Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus

被引：2
作者：
Kaplan, Alyson [1 ]
DeHaan, Elliott [2 ]
Maltz, Charles [1 ]
机构：
[1] New York Presbyterian, Dept Med, Div Gastroenterol & Hepatol, Weill Cornell Sch Med, New York, NY 10065 USA
[2] New York Presbyterian, Dept Med, Div Infect Dis, Weill Cornell Sch Med, New York, NY USA
来源：
ACG CASE REPORTS JOURNAL | 2021年 / 8卷 / 05期
关键词：
MONOCLONAL-ANTIBODY; HIV-1;
D O I：
10.14309/crj.0000000000000594
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Despite the decreasing morbidity associated with the human immunodeficiency virus (HIV), a large percentage of persons with HIV have at least 1 drug resistance mutation. Ibalizumab, a recently approved drug, targets multidrug-resistant HIV. We present a case of reactivation of hepatitis B after initiation of ibalizumab therapy.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Ibalizumab for the treatment of multidrug-resistant HIV-1 infection
    Rizza, S. A.
    Bhatia, R.
    Zeuli, J.
    Temesgen, Z.
    DRUGS OF TODAY, 2019, 55 (01) : 25 - 34
  • [2] Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection
    Blair, Hannah A.
    DRUGS, 2020, 80 (02) : 189 - 196
  • [3] Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1
    Emu, Brinda
    Fessel, Jeffrey
    Schrader, Shannon
    Kumar, Princy
    Richmond, Gary
    Win, Sandra
    Weinheimer, Steven
    Marsolais, Christian
    Lewis, Stanley
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (07) : 645 - 654
  • [4] Vertical transmission of multidrug-resistant Q151M human immunodeficiency virus type 1 strains
    Henry, Mireille
    Thuret, Isabelle
    Solas, Caroline
    Genot, Severine
    Colson, Philippe
    Tamalet, Catherine
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2008, 27 (03) : 278 - 280
  • [5] Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy
    Ohishi, Waka
    Chayama, Kazuaki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2011, 15 (05) : 634 - 640
  • [6] Hepatitis B virus/human immunodeficiency virus coinfection: interaction among human immunodeficiency virus infection, chronic hepatitis B virus infection, and host immunity
    Li Yi-jia
    Wang Huan-ling
    Li Tai-sheng
    CHINESE MEDICAL JOURNAL, 2012, 125 (13) : 2371 - 2377
  • [7] Prevention of hepatitis B virus reactivation under rituximab therapy
    Tsutsumi, Yutaka
    Yamamoto, Yoshiya
    Tanaka, Junji
    Asaka, Masahiro
    Imamura, Masahiro
    Masauzi, Nobuo
    IMMUNOTHERAPY, 2009, 1 (06) : 1053 - 1061
  • [8] Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug Resistant HIV-2 Infection
    Bachelard, Antoine
    Le Hingrat, Quentin
    Ferre, Valentine-Marie
    Le, Minh
    Peytavin, Gilles
    Damond, Florence
    Charpentier, Charlotte
    Goudot, Guillemette Fremont
    de Bouille, Jeanne Goupil
    Lariven, Sylvie
    Delobel, Pierre
    Yazdanpanah, Yazdan
    Descamps, Diane
    Matheron, Sophie
    Ghosn, Jade
    CLINICAL INFECTIOUS DISEASES, 2024, 78 (04) : 1005 - 1010
  • [9] Acceptable Plasma Concentrations of Raltegravir and Etravirine When Administered by Gastrostomy Tube in a Patient with Advanced Multidrug-Resistant Human Immunodeficiency Virus Infection
    Sandkovsky, Uriel
    Swindells, Susan
    Moore, Ryan
    Acosta, Edward P.
    Fletcher, Courtney V.
    PHARMACOTHERAPY, 2012, 32 (02): : 142 - 147
  • [10] In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant Human Immunodeficiency Virus Type 1 in the Absence of Lamivudine
    Paredes, Roger
    Sagar, Manish
    Marconi, Vincent C.
    Hoh, Rebecca
    Martin, Jeffrey N.
    Parkin, Neil T.
    Petropoulos, Christos J.
    Deeks, Steven G.
    Kuritzkes, Daniel R.
    JOURNAL OF VIROLOGY, 2009, 83 (04) : 2038 - 2043
12345